LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for th ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is expected to begin in Q1 2025 LAWRENCEVILLE, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OV ...

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the "Company"), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company's common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total ...

As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. 333-281834 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMUNON, INC. (Exact name of registrant as specified in its charter) DELAWARE 52-1256615 (State or other jurisdiction of incorporation or organization) 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 (609) 896-9100 (Address, including zip code ...

September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will hold its first Ovarian Cancer R&D Day on September 18, 2024 at the Harvard Club (35 West 44th Street) in New York City. The event will feature pr ...

As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMUNON, INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 (609) 896-9100 (Address, including zip code, and telephone number, including area code, of Registrant's principal exe ...

R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer IMUNON LHA Investor Relations David Gaiero Kim Sutton Golodetz 978-376-6352 212-838-3777 dgaiero@imunon.com kgolodetz@lhai.com Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark th ...

Core Viewpoint - IMUNON, Inc. is set to host a conference call on August 14, 2024, to discuss its Q2 2024 financial results and provide updates on its clinical development programs, particularly focusing on IMNN-001 for ovarian cancer and its PlaCCine modality for next-generation vaccines [1]. Group 1: Company Overview - IMUNON is a clinical-stage biotechnology company that develops DNA-mediated immunotherapy and next-generation vaccines, utilizing non-viral DNA technology [4]. - The company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy currently in Phase 2 development for advanced ovarian cancer, designed to produce cancer-fighting molecules at the tumor site [5]. Group 2: Clinical Development Programs - IMNN-001 targets first-line, locally advanced-stage ovarian cancer and aims to instruct the body to generate durable levels of IL-12 and interferon gamma at the tumor site [5]. - The PlaCCine modality is a proprietary DNA plasmid technology aimed at delivering viral antigens to elicit strong immunological responses for vaccine development [1][4]. Group 3: Conference Call Details - The conference call will take place at 11:00 a.m. ET on August 14, 2024, with participation options available via toll-free and international dialing [2]. - An archived replay of the call will be accessible until August 28, 2024, with specific access codes provided for listeners [3].

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and nextgeneration vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 ...

Core Insights - IMUNON, Inc. announced positive topline results from the Phase 2 OVATION 2 Study of IMNN-001, demonstrating a significant improvement in overall survival (OS) for patients with advanced ovarian cancer compared to standard-of-care treatment [1][3][8] - The study showed a hazard ratio of 0.74 in the intent-to-treat population, indicating a 35% improvement in survival, with a median OS increase of 11.1 months [7][19] - IMUNON plans to initiate a registrational study in Q1 2025 and is preparing for an End-of-Phase 2 meeting with the U.S. FDA [1][10] Study Design and Results - The OVATION 2 Study was a randomized trial evaluating the safety and efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer [2][12] - A total of 112 patients were enrolled and randomized 1:1 to receive either IMNN-001 plus standard-of-care chemotherapy or standard-of-care alone [2] - The primary endpoint of progression-free survival (PFS) showed a three-month improvement for the IMNN-001 treatment arm, with a hazard ratio of 0.79, indicating a 27% improvement in delaying progression [17] Clinical Significance - The results indicate that the addition of IMNN-001 could extend median OS from 29 months with standard treatment to 40 months, which is considered clinically meaningful [3][19] - Among patients receiving three or more doses of IMNN-001, there was a further increase in median OS by 15.7 months, with a hazard ratio of 0.64, representing a 56% improvement in survival [7][9] - For patients treated with a PARP inhibitor, the hazard ratio decreased to 0.41, with median OS not yet reached in the IMNN-001 arm compared to 37.1 months in the control arm [7][19] Future Directions - IMUNON aims to advance IMNN-001 into a Phase 3 pivotal study as soon as possible, with plans to present full study results at an upcoming medical conference [8][10] - The company is focused on addressing the unmet medical needs of over 300,000 women diagnosed with advanced ovarian cancer annually [8][12]